TAC

DRUG4 trials

Sponsors

GBG Forschungs GmbH, Peking University People's Hospital, ITB-Med LLC

Conditions

Breast CancerImmune ThrombocytopeniaLiver TransplantationRenal Transplantation

Phase 2

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Peking University People's HospitalImmune Thrombocytopenia

Start: 2022-03-02End: 2023-06-01Target: 120Updated: 2022-07-22

A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruitingNCT05669001

ITB-Med LLCRenal Transplantation

Start: 2023-12-28End: 2026-04-30Updated: 2026-01-14

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active, not recruitingNCT06019507

ITB-Med LLCLiver Transplantation

Start: 2022-06-29End: 2029-06-30Target: 12Updated: 2024-11-27

Phase 3

Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

CompletedNCT00544765

GBG Forschungs GmbHBreast Cancer

Start: 2002-09-30End: 2008-02-29Updated: 2021-02-04

Related Papers

Tacrolimus and Danazol Combination As a Second-Line Therapeutic Strategy for Steroid-Resistant or Relapsed Immune Thrombocytopenia: A Prospective, Randomized, Multicenter, Open-Label Study

Blood2023-11-02

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.

2022-10-051 citations

Eine mdm2 Genamplifikation ist mit Progression und Metastasierung desluminalen Mammakarzinoms im humanisierten Tumormausmodell (hPDX) assoziiert,sowie mit einem ungünstigen klinischen Verlauf derErkrankung

Senologie - Zeitschrift für Mammadiagnostik und -therapie2022-06-01

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

2014-10-2964 citations

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.

2014-07-2861 citations

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

2012-01-1236 citations